Theriva Biologics Inc (TOVX)

[salgovernale69]

I hope you are right. However, I'm not too worried about it. When I spoke to Vincent from the third party IR company he told me the company hasn't changed their timeline as of now, but gave the standard expected disclaimer of "but anything is possible." However, he did say that they've met the enrollment requirement which tells me that if there happens to be a delay in data it would likely be very brief.

I still anticipate them to meet the guided timeline of Q3, but as many on here have pointed out, if we get the Phase 2b announcement this quarter and data say on October 7th, it's really no different. Sure there may be some impatient sellers on the 30th who think it's a major delay but as long as we get the Phase 2b, who really cares? Data has been good every step of the way and if they are clear to proceed with the Phase 2b and they are advancing the trials, data on 12 patients doesn't seem as important. For me it's all about advancing trials and thus driving the valuation higher. We already know the data will likely be good, because they told us it was good on 4 of 12 and Riley alluded to them not having to enroll more patients because they were so happy with the data.